Our story starts with the vision of an immunologist…
We began with a bold solution to a long-standing puzzle in immune theory.
Founded in 2003 by immunologist Dr. Geoffrey Hoffmann after a long academic career at the University of British Columbia, NI emerged from his work on immune network theory and the unresolved IJ paradox—a key reason the theory was abandoned in the 1980s. Dr. Hoffmann’s discovery of symmetrical immune network theory offered a breakthrough, revealing how the immune system operates as a dynamic, interconnected network. This insight inspired a new vision: to develop technologies that restore immune balance rather than suppress immune function.
Early efforts focused on immune modulation for HIV prevention. While results were inconclusive, this foundational work set the stage for what came next. In 2010, George Hoffmann joined the company full-time, and by 2012, the concept for a revolutionary immune-stabilizing technology began to take shape.
Moving from discovery to development
In 2014, experimental immunologist Dr. Reginald Gorczynski joined the team, working with Dr. Geoffrey Hoffmann to develop AbstimX™—a platform technology designed to rebalance the adaptive immune system.
From 2014 to 2020, the team ran several proof-of-principle studies, showing that AbstimX™ could help prevent or treat a range of immune-related conditions, including peanut allergy in dogs, egg allergy and colitis in mice, transplant rejection, and inflammatory breast cancer. These results were published in five peer-reviewed papers.
By 2021, Network Immunology was ready to grow. A new scientific and executive team stepped in, focused on commercialization. With strong preclinical results and a clear market need, canine allergy treatment became the first target—while still building toward long-term human health applications.
The future of immune therapy is already underway.
In 2024, Network Immunology partnered with the University of Florida to launch our first canine clinical trial, which began in early 2025. This trial marks a major step in translating our science into solutions—starting with allergic disease in companion animals. Early progress is promising, and we’re already laying the groundwork for what comes next.
We’re also forming key partnerships to bring our platform to market and scaling up preparations for human clinical trials focused on allergies and autoimmune conditions. These efforts represent the next phase of our mission: delivering therapies that work with the immune system to restore balance, rather than suppress it.
From academic theory to real-world impact, Network Immunology is redefining how we approach chronic immune conditions—through innovative science, strong partnerships, and a commitment to changing lives, both human and animal.